[Clinical study of XXXX (author's transl)].

@entity1 @entity308 @entity52125 @entity146 @entity148 @entity716 @entity4696
An open study of @entity52125 has been achieved in a @entity146 unit. The drug has been prescribed to 36 @entity1 , all comers, half of them aged 60. Out of them 28 are affected by a @entity308 , six by a @entity308 . In terms of the importance of the @entity308 signs, medium posologies (300 mg a day) or strong ones (600 mg a day) are used. The total result is excellent or good in 65% of the cases: it becomes evident in more than one case out of two during the first week. To get it the treatment must absolutely be extended and process to higher posologies may be necessary. @entity4696 and the @entity308 phase of chronic @entity716 constitute the best terms of @entity52125 . Hypnotics have to be associated but systematic prescription of @entity148 relieving is to be avoided. Tolerance is satisfactory in three cases out of four and the drug is free from the clinical counter-indications belonging to anti-depressants. This allows us to prescribe it to old age in high posologies without any harm.
